RT Journal Article
T1 Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer
A1 Otero Estevez, Olalla
A1 Gallardo Gomez, María
A1 Páez de la Cadena Tortosa, María
A1 Rodríguez Berrocal, Francisco Javier
A1 Cubiella Fernández, Joaquín
A1 Hernandez Ramirez, Vicent
A1 García Nimo, Laura
A1 De Chiara Prada, Loretta
K1 3201.01 Oncología
K1 3210 Medicina Preventiva
K1 3212 Salud Publica
AB Aberrant DNA methylation detected in liquid biopsies is a promising approach for colorectal cancer (CRC) detection, including premalignant advanced adenomas (AA). We evaluated the diagnostic capability of serum NEUROG1 methylation for the detection of AA and CRC. A CpG island in NEUROG1 promoter was assessed by bisulfite pyrosequencing in a case-control cohort to select optimal CpGs. Selected sites were evaluated through a nested methylation-specific qPCR custom assay in a screening cohort of 504 asymptomatic family-risk individuals. Individuals with no colorectal findings and benign pathologies showed low serum NEUROG1 methylation, similar to non-advanced adenomas. Contrarily, individuals bearing AA or CRC (advanced neoplasia—AN), exhibited increased NEUROG1 methylation. Using >1.3518% as NEUROG1 cut-off (90.60% specificity), 33.33% of AN and 32.08% of AA were identified, detecting 50% CRC cases. Nonetheless, the combination of NEUROG1 with fecal immunochemical test (FIT), together with age and gender through a multivariate logistic regression resulted in an AUC = 0.810 for AN, and 0.796 for AA, detecting all cancer cases and 35–47% AA (specificity 98–95%). The combination of NEUROG1 methylation with FIT, age and gender demonstrated a convenient performance for the detection of CRC and AA, providing a valuable tool for CRC screening programs in asymptomatic individuals.
PB Diagnostics
SN 20754418
YR 2020
FD 2020-06-28
LK http://hdl.handle.net/11093/1745
UL http://hdl.handle.net/11093/1745
LA eng
NO Diagnostics, 10(7): 437 (2020)
NO Instituto de Salud Carlos III | Ref. PI15/02007
DS Investigo
RD 23-ene-2025